Raleigh Capital Management Inc. Increases Stock Position in Becton, Dickinson and Company (NYSE:BDX)

Raleigh Capital Management Inc. boosted its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 4,067.4% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,792 shares of the medical instruments supplier’s stock after buying an additional 1,749 shares during the quarter. Raleigh Capital Management Inc.’s holdings in Becton, Dickinson and Company were worth $432,000 as of its most recent SEC filing.

Several other hedge funds also recently bought and sold shares of the stock. WR Wealth Planners LLC boosted its stake in Becton, Dickinson and Company by 1.4% during the second quarter. WR Wealth Planners LLC now owns 2,978 shares of the medical instruments supplier’s stock worth $696,000 after buying an additional 42 shares during the period. Key Client Fiduciary Advisors LLC boosted its stake in Becton, Dickinson and Company by 2.6% during the first quarter. Key Client Fiduciary Advisors LLC now owns 1,715 shares of the medical instruments supplier’s stock worth $424,000 after buying an additional 43 shares during the period. Clear Creek Financial Management LLC boosted its stake in Becton, Dickinson and Company by 5.1% during the second quarter. Clear Creek Financial Management LLC now owns 900 shares of the medical instruments supplier’s stock worth $210,000 after buying an additional 44 shares during the period. Sound Income Strategies LLC boosted its stake in Becton, Dickinson and Company by 35.8% during the third quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier’s stock worth $40,000 after buying an additional 44 shares during the period. Finally, Central Pacific Bank Trust Division boosted its stake in shares of Becton, Dickinson and Company by 22.5% in the third quarter. Central Pacific Bank Trust Division now owns 245 shares of the medical instruments supplier’s stock valued at $59,000 after purchasing an additional 45 shares during the period. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Stock Down 0.4 %

Shares of Becton, Dickinson and Company stock opened at $239.66 on Wednesday. Becton, Dickinson and Company has a 52-week low of $218.75 and a 52-week high of $262.23. The company has a 50 day moving average of $237.20 and a 200 day moving average of $235.12. The company has a quick ratio of 1.36, a current ratio of 1.85 and a debt-to-equity ratio of 0.70. The company has a market capitalization of $69.26 billion, a P/E ratio of 52.79, a P/E/G ratio of 1.79 and a beta of 0.42.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings data on Thursday, August 1st. The medical instruments supplier reported $3.50 earnings per share for the quarter, topping analysts’ consensus estimates of $3.31 by $0.19. Becton, Dickinson and Company had a net margin of 7.13% and a return on equity of 14.49%. The company had revenue of $4.99 billion for the quarter, compared to analysts’ expectations of $5.08 billion. During the same quarter last year, the company earned $2.96 earnings per share. The firm’s revenue for the quarter was up 2.3% on a year-over-year basis. As a group, research analysts forecast that Becton, Dickinson and Company will post 13.11 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on BDX. Stifel Nicolaus raised their price objective on shares of Becton, Dickinson and Company from $270.00 to $280.00 and gave the company a “buy” rating in a research note on Friday, July 26th. StockNews.com raised shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research note on Thursday, August 8th. Raymond James lowered their price objective on shares of Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating for the company in a research note on Friday, August 2nd. Evercore ISI raised their price objective on shares of Becton, Dickinson and Company from $286.00 to $290.00 and gave the company an “outperform” rating in a research note on Tuesday, October 1st. Finally, Citigroup raised shares of Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and raised their price objective for the company from $255.00 to $275.00 in a research note on Tuesday, October 1st. Nine research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $282.63.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.